Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing.

Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, Goldberg JD, Li X, Riddle E, Smirnakis K, Kasliwal R, Ren Z, Hotermans C, Ho PR, Campbell N.

Neurology. 2019 Oct 8;93(15):e1452-e1462. doi: 10.1212/WNL.0000000000008243. Epub 2019 Sep 12.

PMID:
31515290
2.

Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.

Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L.

BMC Neurol. 2019 Jun 8;19(1):116. doi: 10.1186/s12883-019-1337-z.

3.

Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.

Gudesblatt M, Wissemann K, Zarif M, Bumstead B, Fafard L, Wilken J, Blitz K, Buhse M, Santra S, Hotermans C, Lee L.

CNS Drugs. 2018 Dec;32(12):1183. doi: 10.1007/s40263-018-0574-9.

4.

Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.

Gudesblatt M, Wissemann K, Zarif M, Bumstead B, Fafard L, Wilken J, Blitz K, Buhse M, Santra S, Hotermans C, Lee L.

CNS Drugs. 2018 Dec;32(12):1173-1181. doi: 10.1007/s40263-018-0553-1. Erratum in: CNS Drugs. 2018 Sep 22;:.

5.

Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).

Cohan SL, Moses H, Calkwood J, Tornatore C, LaGanke C, Smoot KE, Meka V, Okwuokenye M, Hotermans C, Mendoza JP, Mann MK, Meltzer LA.

Mult Scler Relat Disord. 2018 May;22:27-34. doi: 10.1016/j.msard.2018.02.028. Epub 2018 Feb 26.

6.

Clinical Significance of Gastrointestinal and Flushing Events in Patients with Multiple Sclerosis Treated with Delayed-Release Dimethyl Fumarate.

Phillips JT, Selmaj K, Gold R, Fox RJ, Havrdova E, Giovannoni G, Abourjaily H, Pace A, Novas M, Hotermans C, Viglietta V, Meltzer L.

Int J MS Care. 2015 Sep-Oct;17(5):236-43. doi: 10.7224/1537-2073.2014-069.

7.

Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis.

Kappos L, Giovannoni G, Gold R, Phillips JT, Arnold DL, Hotermans C, Zhang A, Viglietta V, Fox RJ; DEFINE and CONFIRM study investigators.

Eur J Neurol. 2015 Apr;22(4):664-71. doi: 10.1111/ene.12624. Epub 2015 Jan 2.

8.

Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM.

Voloshyna N, Havrdová E, Hutchinson M, Nehrych T, You X, Belachew S, Hotermans C, Paes D.

Eur J Neurol. 2015 Mar;22(3):570-7. doi: 10.1111/ene.12618. Epub 2014 Dec 15.

9.

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.

Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, Zhang A, Hotermans C, Belachew S; TYSABRI Observational Program (TOP) Investigators.

J Neurol Neurosurg Psychiatry. 2014 Nov;85(11):1190-7. doi: 10.1136/jnnp-2013-306936. Epub 2014 Feb 14.

10.

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.

Kappos L, O'Connor PW, Polman CH, Vermersch P, Wiendl H, Pace A, Zhang A, Hotermans C.

J Neurol. 2013 May;260(5):1388-95. doi: 10.1007/s00415-012-6809-7. Epub 2013 Jan 5.

11.

Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.

N Engl J Med. 2012 May 17;366(20):1870-80. doi: 10.1056/NEJMoa1107829.

12.

Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.

Weinstock-Guttman B, Galetta SL, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, O'Connor PW, Phillips JT, Polman C, Stuart WH, Lynn F, Hotermans C.

J Neurol. 2012 May;259(5):898-905. doi: 10.1007/s00415-011-6275-7. Epub 2011 Oct 19.

PMID:
22008873
13.

Comparison of the timed 25-foot and the 100-meter walk as performance measures in multiple sclerosis.

Phan-Ba R, Pace A, Calay P, Grodent P, Douchamps F, Hyde R, Hotermans C, Delvaux V, Hansen I, Moonen G, Belachew S.

Neurorehabil Neural Repair. 2011 Sep;25(7):672-9. doi: 10.1177/1545968310397204. Epub 2011 Mar 24.

PMID:
21436388
14.

Severe liver dysfunction in a patient with multiple sclerosis: the guilty party is not always the disease-modifying therapy.

Hotermans C, Belachew S, Moonen G, Delwaide J.

Mult Scler. 2009 Nov;15(11):1378-9. doi: 10.1177/1352458509345910. No abstract available.

PMID:
19965562
15.

Repetitive transcranial magnetic stimulation over the primary motor cortex disrupts early boost but not delayed gains in performance in motor sequence learning.

Hotermans C, Peigneux P, de Noordhout AM, Moonen G, Maquet P.

Eur J Neurosci. 2008 Sep;28(6):1216-21. doi: 10.1111/j.1460-9568.2008.06421.x. Epub 2008 Sep 9.

PMID:
18783369
16.

[Therapeutic armamentarium in neurology: the birth of a new era].

Belachew S, Magis D, Lievens I, Cuvelier ML, Rikir E, Garraux G, Hotermans C, Salmon E, Sadzot B, Cambron L, Maquet P, Poirrier R, Moonen G.

Rev Med Liege. 2007 May-Jun;62(5-6):432-48. Review. French.

17.

Therapeutic use of high-frequency repetitive transcranial magnetic stimulation in stroke.

Hotermans C, Peigneux P, Moonen G, Maertens de Noordhout A, Maquet P.

Stroke. 2007 Feb;38(2):253; author reply 254. Epub 2006 Dec 14. No abstract available.

PMID:
17170361
18.

Early boost and slow consolidation in motor skill learning.

Hotermans C, Peigneux P, Maertens de Noordhout A, Moonen G, Maquet P.

Learn Mem. 2006 Sep-Oct;13(5):580-3. Epub 2006 Sep 15.

PMID:
16980543
19.

Prophylaxis of the epilepsies: should anti-epileptic drugs be used for preventing seizures after acute brain injury?

Grisar T, Bottin P, de Borchgrave d'Alténa V, Brichart C, Delcourt C, Dubru JM, Foulon M, Ghariani S, Hotermans C, Legros B, Ossemann M, Sadzot B, Tugendhaft P, Van Bogaert P, van Rijckevorsel K, Verheulpen D.

Acta Neurol Belg. 2005 Mar;105(1):5-13. Review.

PMID:
15861989
20.

[Primary orthostatic tremor].

Bottin P, Sadzot B, Hotermans C.

Rev Med Liege. 2005 Feb;60(2):96-100. French.

21.

[How I treat ... essential tremor].

Delcourt C, Hotermans C, Sadzot B.

Rev Med Liege. 2003 Nov;58(11):661-5. Review. French.

22.

Therapeutic issues in women with epilepsy.

Legros B, Bottin P, de Borchgrave V, Delcourt C, de Tourtchaninoff M, Dubru JM, Foulon M, Ghariani S, Grisar T, Hotermans C, Ossemann M, Sadzot B, Tugendhaft P, Van Bogaert P, van Rijckevorsel K, Verheulpen D.

Acta Neurol Belg. 2003 Sep;103(3):135-9.

PMID:
14626692
23.

[Reversible posterior leukoencephalopathy syndrome].

Hotermans C, Bottin P, Sadzot B, Moonen G.

Rev Med Liege. 2003 Jul-Aug;58(7-8):472-8. French.

24.

Population dynamics of CD4+ T cells lacking Thy-1 in murine retrovirus-induced immunodeficiency syndrome (MAIDS).

Moutschen MP, Colombi S, Deprez M, Van Wijk F, Hotermans C, Martin MT, Greimers R, Boniver J.

Scand J Immunol. 1994 Feb;39(2):216-24.

25.

Lymphocyte lifespan in murine retrovirus-induced immunodeficiency.

Moutschen M, Colombi S, Deprez M, Greimers R, Van Wijk F, Hotermans C, Boniver J.

Adv Exp Med Biol. 1994;355:177-81. No abstract available.

PMID:
7709819

Supplemental Content

Loading ...
Support Center